Abnormal Expression of Prostaglandins E2 and F2α Receptors and Transporters in Patients with Endometriosis

Table 2

Effect of endometriosis and menstrual cycle phase on expression of prostaglandin receptors and transporters in endometrium, based on real-time PCR and normalized relative to GAPDH mRNA as mean % ± SD. Also, = 30, 50, and 28, respectively, for healthy (control) subjects, eutopic tissue samples from endometriosis patients, and ectopic tissue samples.

Gene	Controls; (mean ± SEM)	Endometriosis
		Eutopic; (mean ± SEM)	Ectopic; (mean ± SEM)
EP1
Proliferative phase	317,2 ± 100,5	307,0 ± 42,13	307,3 ± 54,11
Secretory phase	209,5 ± 35,33	200,2 ± 37,57	411,3 ± 128,9
EP2
Proliferative phase	57,90 ± 17,46	66,60 ± 22,24	71,74 ± 14,89
Secretory phase	198,2 ± 51,72^†	179,5 ± 38,82^†	112,6 ± 17,9
EP3
Proliferative phase	28,55 ± 6,652	29,76 ± 3,444	1021 ± 249,3^***+++
Secretory phase	73,94 ± 20,06^†	48,35 ± 6,463^††	1310 ± 276,1^***+++
EP4
Proliferative phase	34,38 ± 12,67	46,82 ± 22,68	380,2 ± 136,5^***+
Secretory phase	21,94 ± 6,654	10,47 ± 1,546	583,4 ± 205,2^***+++
FP
Proliferative phase	237,5 ± 31,18	1059 ± 497,2	9213 ± 1947^***+++
Secretory phase	97,27 ± 18,26^††	229,6 ± 61,22^††	14268 ± 2742^***+++
PGT
Proliferative phase	16,04 ± 4,058	21,74 ± 3,682	56,42 ± 14,73^**+
Secretory phase	5,964 ± 3,326^††	6,760 ± 2,736^†††	88,69 ± 25,28^***+++
MRP4 total
Proliferative phase	142,9 ± 63,47	97,05 ± 15,51	591,5 ± 227^**+
Secretory phase	80,93 ± 16,17	154,7 ± 25,77	931,2 ± 386,5^***+++
MRP4 variant 1
Proliferative phase	160,9 ± 15,28	157,8 ± 18,82	194,2 ± 24,08
Secretory phase	196,2 ± 24,35	178,8 ± 18,99	164,7 ± 20,93

Note: < 0.01 and < 0.001 versus the control group; < 0.05 and < 0.001 versus the eutopic group; < 0.05 and < 0.01 versus expression in the corresponding proliferative phase; .